Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gossip from Yahoo finance conversations (Jake): “ The office space in downtown Calgary that mCloud was supposed to move into, after some big announcements from Russ, now has the mCloud sign removed. Also confirmed with some staff at mCloud that they have not been paid for 4 pay periods now. It would appear, in my opinion, that mCloud could be closing its operations soon unless someone with deep pockets and light on financial knowledge comes along and puts up more cash to keep mCloud a float.”
The comment was dated late January. A follow up post in March from same person alleges employees still haven’t been paid. Sounds like old Russ(Ian) Style: “you pretend to pay us and we pretend to work.” Snarky posts will end when/if I ever get paid.
mCloud provides update on financing activities today: “On December 6, 2022, mCloud announced it had commenced the closing process of initial proceeds from a non-brokered offering of common shares of the Company, originally announced on November 1, 2022 (the "Offering"). mCloud continues to make progress with the Offering. Given the complex requirements to close these proceeds, the Company now expects to complete this Offering around the end of February.”
The kiss of death. When govt officials have denied something several times, you “know” it’s true. When mCloud says something is Going to happen, better beware. At least Wayne hasn’t answered the phone or my emails to confirm the above.
What a nice Holiday Present. mCloud has finally, after more than half a year, gotten its act together, made nice with the SEC, and announced its offering of 9% perpetual bonds. I was a fool to “invest” as much as I did in mCloud. Thank goodness for greater fools. All the best to Prime, DVP, and other investors out there. It has been an interesting year.
In the new, 10th amended F-1:
“We are in the process of applying to have the Series A Preferred Shares sold in this offering listed on the Nasdaq Capital Market (“Nasdaq”) under the symbol “MCLDP”. There is no assurance that our listing application will be approved. We will not consummate this offering unless the Series A Preferred Shares will be listed on the Nasdaq Capital Market. The Warrants will be listed on Nasdaq along with the Listed Warrants (as defined below) under the symbol (“MCLDW”).”
I’m not holding my breath until I get repaid. Maybe next year…
In my email to mCloud yesterday I “declined” to reference scene from The Godfather.
Silly me, I meant Goodfellas:
I have sent email to mCloud people: It is truly frustrating when I can get more information from a bulletin board than from the company. A new press release on regulatory approval/disapproval of your f-1 is in order. I will refrain from making any references to The Godfather movie scenes.
How will Amir spend $23M?
New deposits or another Hobson plant?
I am not worried about new shares issued. Net $23M in cash for UEC more than makes up for dilution. My concern is how long it takes to get a second ISR plant up and running once uranium price increases enough to make production profitable again. If it takes 2-3 years to get a second ISR plant online, there is no guarantee that uranium price is still high.
Thoughts?
I saw Patrick Cox give a presentation last weekend in St Petersburg. After the talk he spoke with several people in the audience while Vaping. He said he was using the Nicobine product but would say nothing about the ingredients in the liquid.
He said he did not know the actual ingredients; that if he Did know the Ingredients, that he could not say anything without bringing the wrath of the FDA down upon the company.
While denying knowledge about the product, he did say that he "felt" that vaping nicobine was beneficial to his health. Heavy emphasis on the verb "felt".
NukeJohn 21555 quotes the UK trial press release: "Quotient Clinical will employ its RapidFACTTM (Rapid Formulation development And Clinical Testing) service to test novel, oral, modified release Anatabine Citrate formulations which have been developed jointly with Rock Creek Pharmaceuticals."
Does "modified release" mean they've come up with time release capsules? If so, I'm at least a little excited.
On Friday 23.9 million shares changed hands, along with another 20 million shares after hours(?). How is it possible for so many shares to trade without changing price of shares? We're any of those shares "short shares" that were supposed to explode price when they had to cover?
Life is unfair. So far we know that anatabine ameliorates inflammation caused by TBI in subjects that are dirty, rotten scoundrels. Does it only help rats?
Hello, I'm new to this board, but an active investor in other biotechs.
The Agora newsletter Breakthrough Technology Alert this afternoon came out with a recommendation for buying TransEnterix up to $9.50, but hedged by saying currently thinly traded and could go down for the next few days.
I checked for news on the company and after close of the day the company announced a public offering of 12,500,000 shares at $4.00 per share. Since only about 50,000,000 shares outstanding, this is impressive dilution. Any comments? Do you trust management?
Funny how we all hear and remember different things. I heard that the primary factor in choosing which disease to go after in first IND was the time it would take to get thru trials. Mullan indicated that they would not be going after AD initially as those trials would take years as opposed to months.
They are still playing things close to vest, and not giving us much pump.
Questions@starscientific.com sent
NukeJohn, I took the liberty of sending in your question to the company
"In the past, Dr. Mullan has discussed a "cocktail" to treat Alzheimer's Disease and he has indicated researchers are getting very close to a solution. I recall that he has indicated that the cocktail consisted of somethijng to reduce inflammation, something to reduce beta amyloid plaque, and something else (which I can't recall).
Roskamp just signed a partenership with Anavex for Alzheimer's research. Are the Anavex drug and Anatabine going to be key components of the cocktail? "
Anybody else has questions, Please send them in. We've got maybe an hour of time that Dr. Mullen can give us, after the hour of "no forward looking statements, promises, and hopes" back covering. Let's make it interesting!
Also sent in your second question:
"Anatabine has been shown to reduce the transcription of NF-kB which leads to inflammation in the body, but I think many people don't take enough to cokmpletely control the inflammation and see the benefits. The proper dosage needs to be determined on each individual, and it needs to be regulated so the user gets enough to reach therapuetic levels. It took me over a year of trail and error to get the right dosage for me. I saw benefits at lower dosages, but maximum benefits at my current dose.
It would be great if there was a way to measure inflammation in the body (ie CRP) with a quick test, just like a diabetic measures his insulin levels. My question would be this....
Is there any quick way to for people to measure the level of inflammation in the body with an easy self-test method like diabetics use for blood sugar? "
Excuse me. I'm an idiot. Instead of reading left to right, or even right to left, after a long day I have apparently been reading bottom to top.
In the previous post I referred to Hadasit as the company Phillip Frost was involved with. The relevant company is actually Protalix Biotherapeutics Inc. Hadasit is the previous company written about, and the newsletter had "Bio Holdings Ltd." in bold print directly above sentence fragment I quoted.
So after reading correctly, I don't know of any rumors about Frost and Hadasit.
Only rumors are from Stephen Petranek in Agora/Breakfthrough Technology Alert (April 2014).
"The second plus (for Hadasit) is the involvement of Phillip Frost in the company."
Questions for Investor & Analyst Meeting are being requested on Star's website.
Please "send your question to: questions@starscientific.com".
My question: Has Star given consideration to an anatabine e-cigarette? Any details?
If we also put our questions on this website, we'll have an idea of how open management is to helping us place a value on the company. If we have LOTS of questions, but Star gives us 15 minutes of boilerplate, and says everything else is confidential, well…..
And the company filed its 10-K with 5 minutes left of trading today, just the way the big boys play.
from 10-k news release: "On March 12, 2014, the Company entered into a series of financing transactions that resulted in gross cash proceeds of approximately $9.3 million and cash availability under a credit facility of approximately $5.8 million (subject to certain conditions and limitations), for total available funds of $15.1 million. This financing is intended to provide support for the Company's ongoing operations, including its plans to file an Investigational New Drug Application ("IND") during the second quarter 2014 and, if permitted by the FDA, to begin a Phase I clinical trial thereafter directed to a specific disease condition."
The only "Nomo" I can place is from the song "Hit the road, Jack." Getting back to STSI...
I'm looking forward to meeting next month. Info on short and long term plans for pharmaceutical strategy. Hope more content than last conference.
If the FDA decides to forbid sales of the "adulterated" anatabine products, they won't be limited to "interstate" sales. Florida sales would also cease.
Wickard v. Filburn back in the 1940s decided that a farmer growing wheat on his own farm for consumption by his own farm animals "affected" interstate commerce and consequently, Everything affects interstate commerce. I'd make a snide comment about $&@?&$ being subject to regulation, but it could give some earnest young bureaucrat ideas.
The 9 minute speech by Dr. Michael Mullan:
introduced Dr. Mullan and Dr. Chapman, new president of Star "who has experience in FDA regulatory affairs";
reiterated that the company would have a dual track approach, that of their "second generation" dietary supplement, and that of a pharmacological approach to compounds;
that Star would be reducing its Virginia footprint, and moving to Sarasota;
and referring to its earlier press release, announced that it was receiving additional time to respond to FDA, and that it was changing its website. In the event of no agreement w FDA, Star may have to drop sales of Anatabloc and Cigrx, and that the company would have no further comments for the indefinite future.
The "safe harbor" statement was almost longer than Mullan's speech. I can understand protecting company from outrageous claims and predictions, but come on guys, give us something!
When I was in my 20s I drove through 20 miles of snow to get to a friend's house so I could listen to a "new" song by Paul McCartney. Late night tv - the song by Wings was "Mary had a little lamb."
I feel about the same way I did back then after listening to the 9 minute broadcast just now.
I try to "pump" myself up, but feel like I just got "dumped" on. Thanks for all the content guys.
I am long. By not selling in October - why sell when it's going to go to the moon? - I walked away from capital gains far in excess of my annual day job. I find it distasteful to realize that some people will willingly destroy a company because they forget to say "Mother may I?" Am I willing to gamble that the b@$t@rd$ will not prevail? Damn straight. Time for some of Sir Toby's neutriceuticals. Good night!
"These statements has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent disease."
Seems that every advertisement in Life Extension magazine, and pretty much all vitamin ads I see, include the above qualifier. As if we'd be interested in a product which was unable to cure, prevent, or ameliorate a disease! Can't say I recall this boilerplate on Star's advertising. Could be memory failure, and I don't recollect any claims of Anatabine Citrate helping with that. Even if it's not intended to.
Similarly , every news release of Star's includes a paragraph on forward looking statements. Often the forward looking qualifier is longer than body of news release.
It almost seems like the FDA would like Star to append to every written communication: "Former company officials donated money to losing politicians; we may be full of s&@t and make no claims for our products, even tho independent researchers sure are doing so. But we won't acknowledge them. We're bigger than that. And still possibly full of s&@t."
Sometimes humiliation and abasement go a long way. YMMV. Happy twelfth night to all!
A product dividend? That would certainly take care of ALL of my holiday shopping.
Has this been done before by ANY company?
From John Mauldin's Outside The Box article yesterday:
"I have recently been able to get my great friend Pat Cox (who knows more about such things than I have forgotten) to agree to come and write for Mauldin Economics. We will shortly be launching a newsletter focused on technologies that have the potential to transform our society — and ways to invest in them. Pat Cox should be a familiar name to readers of Outside the Box, and I can’t tell you how thrilled I am to be able to work together with him, exploring the fascinating new world that is being created all around us."
Pat has probably forgotten more things than John knows regarding biotechnology, rather than other way around. But hey, I don't write 1500+ words every week and give 100 lectures a year. I enjoy reading Mauldin's as well as Cox, and look forward to their collaboration.
Recent eye operation. Nothing a little iocane wouldn't help. Very conceivable.
Unfortunately, According to staff at front desk, Patrick had to cancel for health reasons. (Couldn't take plane and train trip would be 4+ days).
Any other STSI admirers at the conference? Up for lunch?
Re: Professional Disinterest
This is my first post here. STSI is my largest position (and largest potential capital loss). I am in the stock for the long haul.
When professionals are working on peer reviewed articles I assume they do not have a financial interest in the product they are reviewing. Not because they are dishonest and would lie for financial gain, but because of perceived potential conflict.
A similar situation exists for Patrick Cox, the Agora Financial "Breakthrough Technology Alert" writer whose "Live Long & Prosper" article is listed at top of InvestorVillage STSI website.
About 18 years ago, one writer for Agora was accused of pumping and dumping his stock picks. Ever since (I believe) Agora has had the policy that their writers could not have a financial interest in any of the stocks they recommended. Sort of like Caeser's wife.
Mr. Cox has written that he might be better off financially if he resigned his job and just invested in STSI. I'm sure some other writers have quit so they could follow their own recommendations.
Having written the above…the main problem I have with Anatabloc is that it doesn't help memory: remembering to take tablets three or four times a day is an effort for someone who loses his glasses on his forehead.
All the best to all, Butte Bill